SCHEMBL7056673

SCHEMBL7056673

COc1ccc(-c2ncc[nH]2)cc1C=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMPD3 Q9NY59 1/20 0.52
KDM4E B2RXH2 3/20 0.48
ALDH1A1 P00352 3/20 0.48
VCP P55072 1/20 0.47
TLR9 Q9NR96 1/20 0.47
TLR8 Q9NR97 1/20 0.47
TLR7 Q9NYK1 1/20 0.47
NISCH Q9Y2I1 1/20 0.45
LMNA P02545 1/20 0.44
ERN1 O75460 6/20 0.43
MAP3K11 Q16584 1/20 0.42
RAF1 P04049 1/20 0.42
BRAF P15056 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP19A1 P11511 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL770667 0.82 SMPD3 (0.66) SMPD3KDM4EALDH1A1VCPTLR9
SCHEMBL8541773 0.79 SMPD3 (0.58) SMPD3KDM4EALDH1A1VCPTLR9
SCHEMBL6002654 0.78 SMPD3 (0.56) SMPD3KDM4EALDH1A1VCPTLR9
SCHEMBL27963202 0.78 SMPD3 (0.56) SMPD3KDM4EALDH1A1VCPTLR9
SCHEMBL29955668 0.78 NISCH (0.45) SMPD3KDM4EALDH1A1VCPNISCH
SCHEMBL3368911 0.78 SMPD3 (0.56) SMPD3KDM4EALDH1A1VCPTLR9
SCHEMBL27803371 0.78 SMPD3 (0.65) SMPD3KDM4EALDH1A1VCPTLR9
SCHEMBL7055331 0.76 ERN1 (0.51) KDM4EALDH1A1LMNAERN1RAF1
SCHEMBL4508073 0.75 ERN1 (0.69) KDM4EALDH1A1LMNAERN1RAF1
SCHEMBL5803059 0.75 SMPD3 (0.69) SMPD3KDM4EALDH1A1VCPTLR9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030162766-A1 Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists PFIZER INC. 2003-08-28 US disclosed
US-6369074-B1 Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists PFIZER INC. 2002-04-09 US disclosed
US-20010023248-A1 Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists HOWARD HARRY R (US) 2001-09-20 US disclosed
EP-0675886-B1 AMINOMETHYLENE SUBSTITUTED NON-AROMATIC HETEROCYCLES AND USE AS SUBSTANCE P ANTAGONISTS PFIZER (US) 2000-07-05 EP disclosed
US-5854262-A Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists PFIZER INC. (US) 1998-12-29 US disclosed
EP-0806423-A1 Aminomethylene substituted non-aromatic heterocycles and use as substance p antagonists PFIZER INC. (US) 1997-11-12 EP disclosed
EP-0675886-A1 AMINOMETHYLENE SUBSTITUTED NON-AROMATIC HETEROCYCLES AND USE AS SUBSTANCE P ANTAGONISTS PFIZER INC. (US) 1995-10-11 EP disclosed
CN-1092771-A The non-aromatic heterocycles that aminomethylene replaces PFIZER (US) 1994-09-28 CN disclosed
WO-1994013663-A1 AMINOMETHYLENE SUBSTITUTED NON-AROMATIC HETEROCYCLES AND USE AS SUBSTANCE P ANTAGONISTS PFIZER INC. (US) 1994-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010023248-A1 Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists NPY1R, OPRK1, OPRL1 SMPD3 2244/4885KDM4E 1271/4885ALDH1A1 856/4885
US-20030162766-A1 Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists NPY1R, OPRK1, TACR1 SMPD3 2820/4885KDM4E 1245/4885ALDH1A1 1055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.